John Bial active positions
| Companies | Position | Start | End |
|---|---|---|---|
Capsigen, Inc.
 Capsigen, Inc. BiotechnologyHealth Technology Capsigen, Inc. is a company based in Vancouver, WA that is developing the next generation of AAV vectors for gene therapy. The company's end-to-end platform uses customized, diverse libraries and proprietary trade™ technology to identify fully functional vectors that meet disease-specific transduction criteria. Capsigen's fit-for-purpose vectors are designed to deliver the highest level of clinical utility in a rapid and high-throughput manner. The company uses data science and directed evolution to build custom AAV capsids to move patients from hope to cured. John Bial has been the CEO of the company since 2020. | Chief Executive Officer | 29/02/2020 | - |
Career history of John Bial
Former positions of John Bial
| Companies | Position | Start | End |
|---|---|---|---|
Yecuris Corp.
 Yecuris Corp. BiotechnologyHealth Technology Yecuris Corp. offers drug discovery and development services for liver toxicity. Its products and services include In Vitro, In Vivo, Reagents, and Application Data. The company was founded by Markus Grompe in 2007 and is headquartered in Portland, OR. | Director/Board Member | - | - |
| Chief Executive Officer | 17/09/2009 | - | |
| President | - | - |
Statistics
International
| United States | 3 |
Operational
| Chief Executive Officer | 2 |
| Director/Board Member | 1 |
| President | 1 |
Sectoral
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Yecuris Corp.
Yecuris Corp. BiotechnologyHealth Technology Yecuris Corp. offers drug discovery and development services for liver toxicity. Its products and services include In Vitro, In Vivo, Reagents, and Application Data. The company was founded by Markus Grompe in 2007 and is headquartered in Portland, OR. | Health Technology |
Capsigen, Inc.
Capsigen, Inc. BiotechnologyHealth Technology Capsigen, Inc. is a company based in Vancouver, WA that is developing the next generation of AAV vectors for gene therapy. The company's end-to-end platform uses customized, diverse libraries and proprietary trade™ technology to identify fully functional vectors that meet disease-specific transduction criteria. Capsigen's fit-for-purpose vectors are designed to deliver the highest level of clinical utility in a rapid and high-throughput manner. The company uses data science and directed evolution to build custom AAV capsids to move patients from hope to cured. John Bial has been the CEO of the company since 2020. | Health Technology |
- Stock Market
- Insiders
- John Bial
- Experience
